Key result
New approaches to non-clinical safety assessment and multi-sector collaborations are proposed to better identify and mitigate the cardiotoxic risks of cancer therapies.
Highlights the need for novel non-clinical safety assessments and collaborations to address cardiotoxicity risks associated with emerging cancer therapies.
Requires prospective validation before clinical adoption; leaves open whether proposed assessments and collaborations will reduce cardiotoxicity.
Marked successes in treating a wide variety of malignancies in both adults and children have raised concerns about the cardiotoxic sequelae of several mainstream and emerging cancer therapies. There is a critical need for the health care community to more quickly and reliably identify the unique treatment-related cardiac risks facing patients with cancer. Meeting these needs will likely involve identifying new biomarkers of early and reversible cardiotoxicity, designing and optimizing dosing and drug selection, and developing oncology drugs that can be administered with protectant therapies to improve safety profiles. Non-clinical studies offer the opportunity to more thoroughly characterize underlying biological mechanisms that might aid in designing and optimizing safer drugs. The Health and Environmental Sciences Institute (HESI), a global, non-profit institute that promotes multi-sector scientific partnerships along with other academic, government, patient-advocacy, and clinical partners, proposes to develop novel collaborations to develop new ways of performing non-clinical safety assessments that will benefit patient quality of life.
No takes yet. Share an insight, caveat, or question.
Berridge et al. (2014) conducted a review in Cardiotoxicity of cancer therapies. Non-clinical safety assessment was evaluated. New approaches to non-clinical safety assessment and multi-sector collaborations are proposed to better identify and mitigate the cardiotoxic risks of cancer therapies.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: